[Zope-ZEO] Obtain Biotech IPOs! 196
emed11@libero.it
emed11@libero.it
Fri, 19 Jan 2001 12:53:45
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<!-- saved from url=3D(0073)file://C:\WINDOWS\Temporary%20Internet%20File=
s\OLKC225\A0007-1-A2-00.html -->
<HTML><HEAD><TITLE></TITLE>
<META http-equiv=3DContent-Type content=3D"text/html; charset=3Dwindows-1=
252">
<META content=3D"Microsoft FrontPage 4.0" name=3DGENERATOR>
<META content=3DFrontPage.Editor.Document name=3DProgId></HEAD>
<BODY bgColor=3D#cccccc>
<DIV align=3Dcenter>
<TABLE borderColor=3D#003366 cellSpacing=3D5 borderColorDark=3D#003366 ce=
llPadding=3D14=20
width=3D550 borderColorLight=3D#003366 border=3D2>
<TBODY>
<TR>
<TD width=3D"100%" bgColor=3D#ffffff>
<P class=3DMsoBodyText align=3Dcenter><B><FONT face=3DVerdana color=
=3D#003399=20
size=3D4>Help Beta Test Our Site and Be Eligible to Purchase Shares=
of=20
Future IPOs In Which We Participate**</FONT></B></P>
<P class=3DMsoBodyText style=3D"TEXT-ALIGN: left" align=3Dleft><FON=
T face=3DArial=20
size=3D2>eMedsecurities has selected you as a possible participant =
to help=20
test our online stock-trading engine for knowledge-based investing =
in the=20
life sciences. For your cooperation, <B>you will be eligible =
to purchase=20
shares of future IPOs</B> in which we participate, for as long as y=
ou=20
maintain your account with us. This is limited to only <B>50 =
qualified=20
testers! </B><a href=3D"mailto:emedsec@libero.it">Request Mor=
e
Information</a>.**</FONT></P>
<P class=3DMsoBodyText align=3Dcenter><B><FONT face=3DVerdana color=
=3D#003399=20
size=3D3>eMedsecurities=85 The Cure for the Common Portfolio!</FONT=
></B></P>
<P class=3DMsoBodyText style=3D"TEXT-ALIGN: left" align=3Dleft><FON=
T face=3DArial=20
size=3D2>eMedsecurities provides you with a wealth of information, =
all=20
compiled in a single, easy-to-use resource. Learn about new r=
esearch=20
and upcoming treatments for migraine headache, stroke, epilepsy, br=
ain=20
tumor and much more. Obtain critical investment information a=
bout the=20
companies that are developing these treatments. eMedsecuritie=
s empowers=20
you to make more informed investment decisions. <a href=3D"ma=
ilto:emedsec@libero.it">Request
More Information</a>.**</FONT></P>
<P class=3DMsoNormal><B><FONT face=3DArial size=3D2>Participation i=
n
eMedsecurities' Beta Test allows you:</FONT></B></P>
<UL>
<LI>
<P class=3DMsoNormal=20
style=3D"mso-list: l1 level1 lfo2; tab-stops: list .5in; line-hei=
ght: 100%; margin-top: 0; margin-bottom: 0"><B><FONT=20
face=3DArial size=3D2 color=3D"#003399">Eligibility to purchase s=
hares of IPOs in which=20
eMedsecurities participates for as long as you maintain your=20
account**</FONT></B> </P>
<LI>
<P class=3DMsoNormal=20
style=3D"mso-list: l1 level1 lfo2; tab-stops: list .5in; line-hei=
ght: 100%; margin-top: 0; margin-bottom: 0"><B><FONT=20
face=3DArial size=3D2 color=3D"#003399">Valuable research of the =
entire product=20
pipeline of companies, including stages of clinical development, =
by=20
industry or specific disease</FONT></B> </P>
<LI>
<P class=3DMsoNormal=20
style=3D"mso-list: l1 level1 lfo2; tab-stops: list .5in; line-hei=
ght: 100%; margin-top: 0; margin-bottom: 0"><B><FONT=20
face=3DArial size=3D2 color=3D"#003399">Useful information about =
industry trends, recent=20
developments and upcoming IPOs</FONT></B> </P>
<LI>
<P class=3DMsoNormal=20
style=3D"mso-list: l1 level1 lfo2; tab-stops: list .5in; line-hei=
ght: 100%; margin-top: 0; margin-bottom: 0"><B><FONT=20
face=3DArial size=3D2 color=3D"#003399">Commitment to customer se=
rvice featuring=20
our Live Customer Service Online</FONT></B> </P>
<LI>
<P class=3DMsoNormal=20
style=3D"mso-list: l1 level1 lfo2; tab-stops: list .5in; line-hei=
ght: 100%; margin-top: 0; margin-bottom: 0"><B><FONT=20
face=3DArial size=3D2 color=3D"#003399">Dedication to fast trade =
executions at the best=20
possible price</FONT></B> </P>
</UL>
<P align=3Dleft><FONT face=3DArial size=3D2>The following guideline=
s will=20
explain what we expect from an eMedsecurities Beta Tester:</FONT></=
P>
<UL>
<LI>
<P align=3Dleft style=3D"line-height: 100%; margin-top: 0; margin=
-bottom: 0"><FONT face=3DArial size=3D2>Open a funded eMedsecurities=20
account</FONT> </P>
<LI>
<P align=3Dleft style=3D"line-height: 100%; margin-top: 0; margin=
-bottom: 0"><FONT face=3DArial size=3D2>Visit our online trading site onc=
e=20
a week</FONT> </P>
<LI>
<P align=3Dleft style=3D"line-height: 100%; margin-top: 0; margin=
-bottom: 0"><FONT face=3DArial size=3D2>Execute trades through our web=20
site in accordance with your normal practice</FONT> </P>
<LI>
<P align=3Dleft style=3D"line-height: 100%; margin-top: 0; margin=
-bottom: 0"><FONT face=3DArial size=3D2>Submit feedback to eMedsecurities=
' development team through a questionnaire sent via=20
email</FONT> </P>
<LI>
<P align=3Dleft style=3D"line-height: 100%; margin-top: 0; margin=
-bottom: 0"><FONT face=3DArial size=3D2>Provide us with additional=20
feedback regarding the site as needed</FONT> </P></LI></UL>
<P align=3Dleft><FONT face=3DArial size=3D2>The test is limited to =
only 50 Beta=20
Testers so sign up now to be considered! <a href=3D"mailto:em=
edsec@libero.it">Request
More Information</a>.**</FONT>=20
<P align=3Dleft><B><FONT face=3DArial size=3D2>Please note:</FONT><=
/B><FONT=20
face=3DArial size=3D2> All applications for the Beta Test must be s=
ubmitted by
January 24, 2001 to be considered.</FONT>=20
<P align=3Dleft><FONT face=3DArial size=3D2><SPAN=20
style=3D"mso-bidi-font-size: 12.0pt; mso-fareast-font-family: Times=
New Roman; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bi=
di-language: AR-SA">Please=20
be advised that your information will stay in our proprietary datab=
ase and=20
will not be sold, traded, given or otherwise provided to outside ve=
ndors.
We respect your privacy.</SPAN></FONT>=20
<P align=3Dleft>=20
<P align=3Dleft><FONT face=3DArial size=3D1><SPAN=20
style=3D"mso-fareast-font-family: Times New Roman; mso-ansi-languag=
e: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA">By=20
submitting your information, you implicitly state that this is some=
thing=20
that interests you and that you<br>
agree to receive periodic emails from=20
eMedsecurities.</SPAN></FONT>=20
<P class=3DMsoNormal><FONT face=3DArial size=3D1>Research indicated=
that you=20
might benefit from our offer. To be removed instantly and per=
manently from=20
our database, simply <a href=3D"mailto:emed11@libero.it">click here=
</a>.
We respect=20
all removal requests.</FONT></P><FONT face=3DArial size=3D1>**<B> R=
estrictions=20
Apply:</B> <SPAN style=3D"COLOR: red"><B>Beta test not open t=
o residents of:
HI, IL, MI, MN, MS, NE, NH, TN, TX.</B></SPAN> Initial Public=
=20
Offerings are considered speculative investments and as such may no=
t be=20
appropriate for every investor. If an investor chooses to participa=
te in=20
IPOs, there are certain restrictions that apply: <B><SPAN=20
style=3D"COLOR: red">Flipping</SPAN>- </B>The first time an investo=
r sells=20
his/her shares within the first 30 days the issue is trading in the=
=20
secondary market, that investor will not be allocated shares for th=
e next=20
90 days following the sale. The second time that investor =93=
flips=94,=20
they will not be allocated IPO shares for 180 days. The third=
time=20
that investor =93flips=94, they lose their IPO allocations permanen=
tly.<SPAN=20
style=3D"COLOR: red"> <B>Transferring shares</B></SPAN><B>- <=
/B>If the=20
investor transfers IPO shares out of their account within the first=
30=20
days the issue is trading in the secondary market, they will perman=
ently=20
lose their IPO allocations. <B>Beta investors will be chosen =
from=20
all the applicants based on their income, net worth and investing=20
experience. </B> IPO shares will only be allocated from transa=
ctions in=20
which eMedsecurities participates in the underwriting. A0007-1-A2</=
FONT>=20
</TD></TR></TBODY></TABLE></DIV></BODY></HTML>